The discovery of an effective vaccine for human immunodeficiency virus type 1 (HIV-1) remains the principal objective to help control the AIDS pandemic (2, 9, 12, 16, 25, 34, 49) . To date, animal testing of candidate vaccines has focused extensively on nonhuman primates (macaques), since these animals can be readily challenged with infectious, pathogenic, simian immunodeficiency viruses (SIV) and HIV/SIV chimeras (27, 29, 31, 59) . This permits direct evaluation of the protective potential of candidate vaccines. On balance, nonhuman primate models have significant disadvantages, which include cost, availability, uncertain value in predicting human immune responses, and the molecular and immunogenetic diversity of SIV, HIV/SIV, and HIV (14, 21, 22, 40, 59) . Nonetheless, the limited species tropism of HIV makes finding relevant animal models for vaccine testing difficult. Although small-animal models (mice and rabbits) have been used to test the immunogenicity of HIV-1 antigens (7, 19, 45, 62) , they cannot be used to evaluate protection from live-virus challenge. Mice, in particular, may generate strong immune responses to candidate viral vaccines, which subsequently prove to be less immunogenic in nonhuman primates and humans (32) . An ideal animal model system for evaluation of candidate HIV-1 vaccines should incorporate human antigen presenting cells and effector cells, while also permitting direct virus challenge with infectious, pathogenic HIV-1. Within this context, we considered previous experiences using human-mouse chimeras for vaccine testing. Severe combined immunodeficient (SCID) mice reconstituted with human peripheral blood lymphocytes (hu-PBL-SCID mice) develop immune responses to viral antigens (11, 38, 47, 55) . Moreover, the model was utilized extensively in our laboratories and by others to study HIV-1 pathogenic mechanisms and for drug testing (33, 37, 39, 43, 44, 55, 56) . Nonetheless, a limitation of the hu-PBL-SCID mouse model is the relatively modest level of T-cell engraftment and the dearth of human dendritic cells (DC) in the model system (6, 53) . Introduction of exogenous human DC improve the model's value for vaccine testing (28, 61) , linked to the potent antigen-presenting and T-cell stimulatory properties of the DC (5, 50, 51) .
Due to the limitations of the hu-PBL-SCID mouse model, we elected to use a mouse-human chimeric model system, based on nonobese diabetic (NOD)/SCID mice. These animals allow efficient T-cell engraftment (17, 18, 42) . NOD/SCID mice were engrafted with hu-PBL, and the resulting hu-PBL-NOD/SCID mice were immunized with autologous human DC transduced ex vivo with a helper-free herpes simplex virus type 1 (HSV-1) amplicon vector encoding HIV-1 gp120 (HSV gp120 amplicons). Human cellular and humoral immune responses and infectious virus challenge were recorded after vaccination. The studies revealed that HSV gp120 amplicontransduced DC immunization induced significant envelopespecific human adaptive immune responses. Subsequent experiments revealed that the vaccinated animals were partially protected against infectious virus challenge. These data support the utility of this model as a novel preclinical testing system for HIV-1 vaccines.
sacrificed at each time point. Samples collected at sacrifice included serum (obtained by cardiac puncture) and spleens (used for cell isolation). HIV-1-specific humoral and cellular immune responses were measured by enzymelinked immunosorbent assay (ELISA), Western blotting, and enzyme-linked immunospot (ELISPOT) assay.
For infectious HIV-1 challenge, hu-PBL-NOD/SCID mice were injected i.p. with 3 ϫ 10 6 autologous DC that had been transduced ex vivo with HSVlac (control) or HSV gp120 MN/LAI (vaccine), on day 5 after PBL reconstitution. Seven days later, the mice were challenged i.p. with infectious HIV-1 LAI or HIV-1 ADA at a dose of either 10 5 or 10 2 50% tissue culture infectious doses (TCID 50 )/mouse, respectively. The challenge virus doses were selected on the basis of previously published studies which have shown that elevated titers of X4-using viruses are required to establish efficient infection in hu-PBL-SCID mice (13) . Each animal group contained five to eight animals. Mice were sacrificed 14 days after challenge and evaluated for humoral and cellular immune responses and viral load. Splenocytes were immunostained with fluorescein isothiocyanate-or phycoerythrin-conjugated Abs specific for human CD3, CD4, CD8, and CD45 (BD Pharmingen) and analyzed by flow cytometry.
Virus strains. HIV-1 LAI was propagated in phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PHA-blasts), and HIV-1 ADA was FIG. 1. Vaccine scheme and analysis of human immune engraftment in hu-PBL-NOD/SCID mice. NOD/SCID mice were injected with anti-asialo-GM1 Ab and anti-CD122 Ab prior to hu-PBL injection. These Abs were given to inhibit mouse NK cell activity and enhance hu-PBL reconstitution. Immunohistology of mouse spleen, lymph node, and liver obtained 14 days after reconstitution shows the presence of a significant number of human cells. Paraffin sections were stained for human vimentin (brown). Magnification, ϫ20. propagated in monocyte-derived macrophages obtained from HIV-1-seronegative donors. Monocyte-derived macrophages were cultured in macrophage colony-stimulating factor, a generous gift from Genetics Institute, Cambridge, Mass., for 7 days before infection. Viral preparations were screened negative for endotoxin (Ͻ10 pg/ml) (Associates of Cape Cod, Woods Hole, Mass.) and mycoplasma (Gen-Probe II; Gen-Probe, San Diego, Calif.). The virus titers were determined on PHA-blasts and were 10 6 and 10 3 TCID 50 /ml for HIV-1 LAI and HIV-1 ADA , respectively. HIV-1 LAI stock was obtained from the NIH AIDS Research and Reference Reagent Program, and HIV-1 ADA was isolated from virus isolated from the peripheral blood mononuclear cells of an AIDS patient with Kaposi's sarcoma (15) .
ELISA and Western blotting for HIV-1-specific Abs. Sera collected from DC-immunized animals were analyzed for HIV-1-specific human IgG by ELISA with HIV-1 MN gp160 (20) and by Western blotting with HIV-1 nitrocellulose strips from Calypte, Alameda, Calif. The strips were incubated overnight in 1:5 diluted serum samples, with shaking at 4°C; horseradish peroxidase conjugated anti-human IgG was used as a secondary Ab. The strips were developed with a chemiluminescent substrate (Pierce Biotechnology, Inc., Rockford, Ill.) and were exposed to X-ray film. HIV-1-seropositive and -negative human sera were used as positive and negative controls at 1:1,000 dilutions, respectively. Viral neutralization tests. Mouse sera were analyzed for their virus-neutralizing Abs in vitro, with PHA-blasts as virus-susceptible target cells. Briefly, sera were serially diluted in RPMI-1640 medium with 10% fetal calf serum, and 10-l aliquots of diluted serum samples were then placed into a 96-well plate in triplicate. To this, 40 l of either HIV-1 LAI or HIV-1 ADA (100 TCID 50 ) was added and incubated at 37°C for 1 h. PHA-blasts were then added to each well (10 5 cells in 150 l of medium, containing 50 U of interleukin-2/ml). After 3 days, cells were washed, and fresh medium with interleukin-2 was added. Supernatants were collected on day seven and virus production was measured by reverse transcriptase (RT) assay. RT was determined by incubating 10 l of supernatant with a reaction mixture consisting of 0.05% NP-40 (Sigma) and [ 3 H]dTTP (2 Ci/mmol; Amersham Corp., Arlington Heights, Ill.) in Tris-HCl buffer (pH 7.9) for 24 h at 37°C. Radiolabeled nucleotides were precipitated on paper filters in an automatic cell harvester (Skatron, Sterling, Va.) by using cold 10% trichloroacetate and 95% ethanol. Incorporated activity was measured by liquid scintillation spectroscopy (24) .
ELISPOT assay. Single-cell suspensions of splenocytes collected from control and vaccinated animals were stimulated with autologous DC loaded with HIV-1 antigens (41) . Briefly, DC were pulsed with a 10-mer peptide (RGPGRAFVT I;Alpha Diagnostics, San Antonio, Tex.) for 1 h at 37°C. This peptide has previously been shown to have the ability to bind to multiple major histocompatibility complex class I molecules, including HLA-A2 and HLA-A3 (1, 4). These cells were used as stimulators to activate HIV-1-specific human T cells present within the mouse splenocyte population. Stimulator and responder cells were plated in human gamma interferon (IFN-␥) Ab-coated, nitrocellulose membrane-lined 96-well microtiter plates at a ratio of 1:10. The ELISPOT assay was performed after 24 to 36 h with reagents obtained from BD Pharmingen. DC loaded with heat-inactivated HIV-1 particles (corresponding to HIV-1 LAI or HIV-1 ADA , incubated at 65°C for 2 h) were also used for stimulation; PHA at a concentration of 1 g/ml was used as a positive control. Unloaded DC were used as nonspecific stimulators (negative control), and ELISPOT values from these cultures were subtracted from those for all other experimental groups to calcu-
FIG. 3. Humoral immune responses in immunized hu-PBL-NOD/SCID mice. (A)
Western blot analysis for HIV-1 gp120 Abs. The nitrocellulose membrane was probed with the following sera: (i) HIV-1-infected patient serum (1:1,000), (ii) pooled serum samples from mice that received DC transduced with HSV gp120 MN/LAI (1:5 dilution), and (iii) pooled serum samples from mice that received DC transduced with a control amplicon vector (HSVlac). Sera were collected and pooled 7 days after DC immunization. Blots were incubated with the secondary Ab, a horseradish peroxidase-conjugated anti-human IgG, and developed with a chemiluminescence substrate. (B) IgG ELISA for HIV-1 envelopereactive Abs in vaccinated mice. Mice were immunized with HSV-transduced DC; 7 days later, the animals were either challenged with infectious HIV-1 (strain HIV-1 ADA or HIV-1 LAI ) or mock challenged (uninfected mice). Serum samples were then collected 14 days after challenge and analyzed by ELISA with an anti-human IgG Ab; the results are shown for pooled serum samples from six to eight mice. Sera from healthy, noninfected mice and HIV-infected patient sera were included in the assay as negative and positive controls, respectively (results not shown). (C) Neutralization assay results with sera from immunized mice. Sera from immunized mice were collected at day 7, following infusion of amplicon-transduced DC (HSV gp120 MN/LAI or HSVlac in the immunized and control populations, respectively). Sera from a total of four mice per group were then pooled and tested for the ability to inhibit HIV infection of PHA-blasts at the indicated dilutions. Neutralization assays were performed with both LAI and ADA viral strains, with an initial MOI of 0.001 (10 2 TCID 50 of cell-free virus was added to 10 5 PHA-blasts). On day 7 after viral infection, virus replication was measured by RT activity in cell-free culture supernatants. Statistical analysis. Data were analyzed using Excel with Student's t test and analysis of variance for comparisons. A P value of Ͻ0.05 was considered statistically significant. All results are presented as means Ϯ standard errors of the mean (SEM). The viral loads in nonvaccinated and vaccinated animals were compared by a nonparametric Wilcoxon test.
RESULTS

HSV gp120 MN/LAI amplicon transduction of human DC.
Helper-free HSV-1 amplicons effectively transduced human DC (60) . DC were infected with HSV gp120 MN/LAI or HSVlac amplicons at an MOI of 1.0 for 2 h and analyzed 48 h later for expression of major histocompatibility complex class II (HLA-DR), costimulatory molecules (CD80 and CD86), and the maturation antigen (CD83). Figure 2 shows the flow cytometric analysis of DC with and without HSV amplicons. The results show that HSV amplicon-treated DC undergo partial maturation when compared to untreated DC. An upregulation of HLA-DR, CD80, CD86, and CD83 expression was observed. The expression of the surface markers was comparable to that of lipopolysaccharide-treated DC, a potent inducer of DC maturation. In addition, 50 to 60% of HLA-DR-positive DC transduced with the HSV gp120 MN/LAI amplicon expressed HIV-1 gp120 on their surface-indicating that amplicon-mediated gene transfer was highly efficient.
Transduced DC were analyzed for their ability to present antigen to T cells by the mixed lymphocyte assay (data not shown). DC could efficiently stimulate T-cell proliferation, consistent with data obtained from previous studies utilizing HSV amplicons (60) .
HSV gp120 MN/LAI amplicons generate HIV-1-specific humoral immune responses. Mice immunized with HSV gp120 MN/LAI -transduced DC produced HIV-1 gp120-specific human IgG in sera at significant levels as detected by Western blot (Fig. 3A) and ELISA tests (Fig. 3B) . The highest titers of HIV-1 gp120-specific human IgG were observed at day 7 after DC immunization, with a titer of 1:160. The second DC immunization did not affect the titer, and the endpoint HIV-1-specific IgG decreased to 1:25 by 21 days after immunization. In contrast, sera from mice injected with HSVlac-transduced DC showed no HIV-1-specific Abs.
Serum from DC-immunized but unchallenged mice contained Ab levels similar to those present in DC-immunized and virus-challenged animals (Fig. 3B) . Ab levels were slightly reduced in HIV-1 LAI -challenged mice compared to HIV-1 ADAchallenged mice. However, no Abs were generated against other HIV proteins after virus challenge (data not shown), and no Env-specific Abs were detected in animals that were not immunized with HSV gp120 MN/LAI . This was true even after infectious virus challenge (Fig. 3B , vaccinated versus control mice for the HIV-1 LAI and ADA groups).
Analysis of virus-neutralizing Abs is shown in Fig. 3C . Sera from immunized animals (i.e., animals which received HSV gp120 MN/LAI -transduced DC) showed neutralizing activity against both LAI and ADA viral strains that was effective at a 1:4 dilution, whereas sera from control animals (animals which received HSVlac-transduced DC) did not show neutralizing activity.
HSV gp120 MN/LAI amplicons generate HIV-1-specific cellular immune responses. Generation of cellular immune responses against HIV-1 is critical in vaccine candidate evaluation. To this end, we monitored virus-specific T-cell responses induced in immunized animals by a human IFN-␥ ELISPOT assay. A significant antigen-specific T-cell response was detected against the immunodominant cytotoxic T lymphocyte epitope peptide (RGPGRAFVTI) and also against heat-inactivated HIV-1 antigen prepared from different HIV-1 strains (LAI Ͼ ADA). HIV-1-specific primary cellular immune responses peaked at day 7 after the first immunization with 270 Ϯ 50 IFN-␥-secreting cells/10 5 human cells. This declined by day 21 after immunization to 55 Ϯ 24 IFN-␥-secreting cells/10 5 human cells, possibly reflecting the gradual decline of primary immune response. After viral challenge, HIV-1-specific cellular immune responses were reduced in ADA-challenged mice but were lost in LAI-challenged animals (Fig. 4) . This may have reflected virus-induced human immune cell depletion in the mice (see Fig. 6 ). could attenuate or prevent viral infection. In challenge experiments, mice were given only one DC immunization, since peak immune responses were detected at day 7. The HIV-1 challenge was then performed at the peak level of immune responses with an X4-using lymphotropic strain (LAI; 10 5 TCID 50 ) and an R5-using macrophage tropic strain (ADA; 10 2 TCID 50 ). A high-titer X4-using lymphotropic strain is necessary to achieve efficient infection of hu-PBL-NOD/SCID mice (13, 37) . The amount of HIV-1 in sera of the mice was then measured following virus challenge by both HIV-1 p24 ELISA and quantitative RT-PCR (to determine the viral RNA copy number). The levels of normalized HIV-1 p24 protein in ADAinfected mice reached 225.7 Ϯ 97.1 pg/ml in control mice inoculated with HSVlac transduced DC versus 69.0 Ϯ 32.9 pg/ml in vaccinated mice inoculated with HSV gp120 MN/LAItransduced DC (P Ͻ 0.08). In LAI-infected mice, no differences between control and vaccinated mice were detected (67.1 Ϯ 46.5 versus 64.7 Ϯ 47.1; P Ͻ 0.97). Analysis of viral RNA copy number in these serum samples yielded very similar results. The number of viral copies in sera of control animals infected with ADA was 4.3 Ϯ 0.2 versus 3.9 Ϯ 0.2 log per ml of plasma in vaccinated (P Ͻ 0.24) mice. In control and vaccinated mice infected with LAI, viral load was similar (3.6 Ϯ 0.2 versus 3.5 Ϯ 0.2 log; P Ͻ 0.82). Since viral load was greatly dependent on the number of engrafted human cells, results from both assays were normalized for the percentage of human CD45 ϩ cells in the spleen of each animal (Fig. 5) . Normalization showed statistically significant downregulation of HIV-1 ADA replication in vaccinated animals (P Ͻ 0.05). Collectively, these results demonstrate partial protection in the immunized animals following challenge with infectious HIV-1 ADA .
HSV gp120 MN/LAI DC immunization protects CD4 ؉ T cells. HIV-1 LAI challenge led to a significant depletion of CD4 ϩ T lymphocytes (Fig. 6) , which was largely prevented in mice inoculated with HSV gp120 MN/LAI -transduced DC. Thus, even though the virus load was not reduced in these animals (Fig. 5) , the engrafted human CD4 ϩ T lymphocytes were significantly protected from virus-induced cytolysis following X4-using lymphotropic virus strain (LAI) infection. In contrast, HIV-1 ADA challenge had no effect on human CD4 ϩ T lymphocyte counts in the hu-PBL-NOD/SCID mice; CD4 ϩ T cell levels, therefore, remained equivalent in both the vaccinated and control animal groups in this case (6.05 Ϯ 2.30 versus 6.16 Ϯ 3.00). This was expected, as HIV-1 ADA does not affect bystander death of CD4 ϩ T cells. autologous human DC suggests that the hu-PBL-NOD/SCID mouse model system can also be used to study a range of vaccine candidates. This may have utility for both the preclinical evaluation of prophylactic vaccines for HIV/AIDS and prophylactic or therapeutic vaccines for cancer. This study, to the best of our knowledge, is the first to use viral vectortransduced DC expressing HIV-1 antigens demonstrating potent immune responses in a mouse model for human disease. HSV-1 has broad cellular tropism that includes DC (35, 60) . The virus also infects mucosal surfaces and has the ability to establish latent infection in the host, which is characterized by the prolonged expression of a small subset of viral genes. The helper-free HSV-1 amplicon system has several advantages for vaccine delivery, including delivery of multiple copies of the packaged DNA to the target cell. Importantly, the packaged amplicon DNA does not express HSV-1 proteins (such as ICP47 or other viral immune modulatory molecules). Furthermore, transduction of human DC with helper-free HSV-1 amplicons is highly efficient and results in phenotypic maturation of the DC (as reflected by rises in cell surface expression of HLA-DR, CD80, CD83, and CD86), without suppressing their immunostimulatory function (as assessed by multilinear regression) (60) . These factors may contribute to the robust immune responses detected in the hu-PBL-NOD/SCID mice that received the HSV gp120 MN/LAI -transduced DC, as DC maturation was shown to be a key factor in generating immune responses in hu-PBL-SCID mice (26, 61) .
DISCUSSION
The same amplicon vector used in the present study (HSV gp120 MN/LAI ) was previously shown to induce potent HIV-1 specific cellular and humoral responses in BALB/c mice (20, 58) . In the present report, we have shown that human DC transduced with this vector elicit robust human humoral and cellular immune responses in hu-PBL-NOD/SCID mice. Such immune responses were comparable to previous reports with HIV-1-pulsed DC-based vaccines (28, 61) . Taken together, these findings support the notion that the broad host range of HSV-1, coupled with its ability to infect DC, makes the HSV-1 amplicon vector an excellent vehicle for antigen delivery and induction of virus-specific immunity (20, 35, 48, 57) .
In the present study, two different virus strains were employed in our challenge experiments. HIV-1 LAI was chosen in part because the LAI V3 loop sequence was incorporated within the HIV-1 gp120 gene contained in the vaccine construct; however, the remainder was derived from HIV-1 MN (20) . HIV-1 ADA was also used for challenge experiments because hu-PBL-SCID mice have been shown to be more susceptible to R5 viruses than X4 viruses (13, 37) . Macrophage tropic viruses are the major transmittable viruses for HIV infection (36, 46) . Partial protection from HIV-1 ADA and none against HIV-1 LAI was observed. This result is less impressive than that previously reported by Yoshida and colleagues (61), who observed complete protection from infectious virus challenge in hu-PBL-SCID mice immunized with autologous HIV-1 pulsed DC. However, there are several differences between the studies. First, we immunized animals once i.p. and examined virus load at 2 weeks after challenge. In contrast, Yoshida and colleagues coinjected the human PBL and antigen-pulsed DC by the intrasplenic route, then followed with a booster DC immunization 5 days later, and measured viral load at 1 week rather than 2 weeks after challenge, as in our study. Second, we used a large amount of viral inoculum of HIV-1 strain LAI (10 5 TCID 50 ), whereas Yoshida et al. (61) and Lapenta et al. (28) used an autologous macrophage tropic viral strain for challenges. Finally, and perhaps most importantly, our experiments involved the transduction of the immunizing DC with a vector that expressed only HIV-1 gp120 with limited neutralizing viral responses. For these reasons, direct comparisons between the studies cannot be made. Rather, we would conclude that these results provide proof of principle for the use of the hu-PBL-NOD/SCID model to assess the induction of primary human immune responses to candidate HIV-1 vaccines and further exploit the model to examine immunizationinduced protection from virus challenge. Significant sparing of the engrafted human CD4 ϩ T-cell population following HIV-1 LAI infection in hu-PBL-NOD/SCID mice injected with HSV gp120 MN/LAI -transduced DC suggests that partial protective immune responses were achieved in the animals. Future efforts will focus on the evaluation of immune responses elicited by amplicon vectors, which express more optimal HIV-1 Env constructs, alone and in combination with other viral antigens (such as Gag, Pol, Nef, and Tat), as well as appropriate molecular adjuvants (3, 10, 54) .
Overall, our results support prior studies demonstrating that DC-based HIV vaccines effectively induce humoral and cellular immune responses in hu-PBL-SCID mice (28, 61) . HSV-1 amplicons effectively transduce DC and elicit high-level viral antigen expression. This facilitates their use in eliciting strong immune responses to encoded HIV-1 antigens, which may persist over time (20) . DC-based vaccine approaches may further extend the utility of this vector system and could (for example) allow one to avoid any deleterious effects associated with preexisting anti-vector immunity (by allowing the performance of vector transduction ex vivo, in the absence of serum Abs). DC vaccine strategies may also have significant utility in therapeutic settings, including not only HIV/AIDS but also cancer (8, 29, 30) . These results further support the use of the hu-PBL-NOD/SCID mouse model for preclinical screening of potential vaccine candidates. Human immune responses and protection against viral challenge can be tested. This may prove to be particularly useful for vaccine candidates that are difficult to test in macaques. Overall, the chimeric mouse model is significant in its ability to evaluate immune responses that regulate HIV infection. Such responses induced by the types of immunization approaches developed in this report are necessary elements for developing an effective HIV vaccine.
